Life science venture capital firm Pappas Ventures has appointed Franz Humer, chairman of pharmaceutical giant Roche, as a venture partner and senior advisor with the firm.
Humer will retire from Roche in March 2014. He was formerly CEO, as well as COO and head of pharmaceuticals for F Hoffmann-La Roche.
“We are honored to have Franz join our team,” said Art Pappas, managing partner of Pappas Ventures. “Throughout his career, he has consistently focused on the importance of innovation in creating products that can make a real difference to patients. He will be invaluable in helping us pursue this same vision.”
Pappas and venture partner Ernie Mario served alongside Humer in the early 1990s as senior executives and board members for Glaxo Holdings.
“I am thrilled to be able to work again with Art and Ernie and the excellent team they have built over the past 20 years,” said Humer. “Pappas Ventures has a proven track record in investing in companies that create truly innovative products, and I am looking forward to contributing to this strategy.”
Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the US and Canada. In the past 18 months, three Pappas Ventures portfolio companies have conducted initial public offerings: Tesaro, LipoScience and Chimerix.
Copyright © 2013 AltAssets